Clinical Profile of Critical Oncological Patients with COVID-19

Authors

  • Ana Karoline Brito de Oliveira Universidade do Estado do Pará (UEPA), Centro de Ciências Biológicas e da Saúde. Marabá (PA), Brasil. https://orcid.org/0000-0002-3610-7454
  • Matheus Sodré de Araújo Universidade do Estado do Pará (UEPA), Centro de Ciências Biológicas e da Saúde. Marabá (PA), Brasil. https://orcid.org/0000-0003-1947-361X
  • Samuel Filipe Lopes Alves Universidade do Estado do Pará (UEPA), Centro de Ciências Biológicas e da Saúde. Marabá (PA), Brasil. https://orcid.org/0000-0003-1437-5674
  • Luiz Euclides Coelho de Souza Filho Universidade do Estado do Pará (UEPA), Centro de Ciências Biológicas e da Saúde. Marabá (PA), Brasil. https://orcid.org/0000-0002-0828-0911
  • Marianne Lucena da Silva Universidade Federal de Jataí. Jataí (GO), Brasil. https://orcid.org/0000-0002-7678-9007
  • Katiane da Costa Cunha Universidade do Estado do Pará (UEPA), Centro de Ciências Biológicas e da Saúde. Marabá (PA), Brasil. https://orcid.org/0000-0001-5361-5090

DOI:

https://doi.org/10.32635/2176-9745.RBC.2023v69n1.3060

Keywords:

COVID-19, SARS-CoV-2, neoplasms, intensive care units

Abstract

Introduction: SARS-CoV-2 infection has a broad clinical spectrum, which can be categorized by its level of severity. Being an oncological patient is described in the literature as an important risk factor for more severe levels of the disease resulting from a state of immunosuppression. Objective: To compare demographic and clinical characteristics among cancer and non-cancer patients with COVID-19 in a referral hospital in the city of Belém, Pará. Method: Retrospective and quantitative study of analysis of medical records of patients diagnosed with COVID-19 between April and July 2020. For data analysis, the relative risk was calculated with a 95% confidence interval and test t. Results: The sample consisted in 53, mostly females (31; 58.49%) ICU patients diagnosed with COVID-19. There was a predominance of the outcome death for the group of cancer patients (27; 81.8%), as well as a greater number of non-neoplastic comorbidities among cancer patients (19; 57.5%). Cancer patients had longer invasive ventilatory support, with a mean of ten days (13; 39.39%). Conclusion: There were differences in demographic characteristics and interventions performed among the groups investigated.

Downloads

Download data is not yet available.

References

Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. doi: https://doi.org/10.1016/S0140-6736(20)30566-3

Goh KJ, Choong MC, Cheong EH, et al. Rapid progression to acute respiratory distress syndrome: review of current understanding of critical illness from coronavirus disease 2019 (COVID-19) Infection. Ann Acad Med Singap. 2020;49(3):108-18. doi: https://doi.org/10.47102/annals-acadmedsg.202057

World Health Organization [Internet]. Geneva: WHO; c2023. Situation report - 70: coronavirus disease 2019 (COVID-19); 2020 Mar 30 [cited 2020 Apr 19]. Available from: https://apps.who.int/iris/bitstream/handle/10665/331683/nCoVsitrep30Mar2020-eng.pdf?sequence=1&isAllowed=y

World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance [Internet]. Geneva: WHO; 2020 Mar 13 [cited 2020 Apr 19]. Available from: https://apps.who.int/iris/handle/10665/331446

Rod JE, Oviedo-Trespalacios O, Cortes-Ramirez J. A brief-review of the risk factors for covid-19 severity. Rev Saúde Publica. 2020;54:60. doi: https://doi.org/10.11606/s1518-8787.2020054002481

Oberg HH, Wesch D, Kalyan S, et al. Regulatory interactions between neutrophils, tumor cells and T cells. Front Immunol. 2019;10:1690. doi: https://doi.org/10.3389/fimmu.2019.01690

Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883-99. doi: https://doi.org/10.1016/j.cell.2010.01.025

Indini A, Rijavec E, Ghidini M, et al. Coronavirus infection and immune system: an insight of COVID-19 in cancer patients. Crit Rev Oncol Hematol. 2020;153:103059. doi: https://doi.org/10.1016/j.critrevonc.2020.103059

Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335-7. doi: https://doi.org/10.1016/S1470-2045(20)30096-6

Lee LY, Cazier JB, Angelis V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020;395(10241):1919-26. doi: https://doi.org/10.1016/S0140-6736(20)31173-9. Erratum in: Lancet. 2020;396(10250):534. doi: https://doi.org/10.1016/S0140-6736(20)31758-X

Al-Quteimat OM, Amer AM. The impact of the COVID-19 pandemic on cancer patients. Am J Clin Oncol. 2020;43(6):452-5. doi: https://doi.org/10.1097/COC.0000000000000712

Liu C, Zhao Y, Okwan-Duodu D, et al. COVID-19 in cancer patients: risk, clinical features, and management. Cancer Biol Med. 2020;17(3):519-27. doi: https://doi.org/10.20892/j.issn.2095-3941.2020.0289

Soares M, Salluh JIF, Torres VBL, et al. Short- and long-term outcomes of critically ill patients with cancer and prolonged ICU length of stay. Chest. 2008;134(3):520-6. doi: https://doi.org/10.1378/chest.08-0359

Biskup E, Cai F, Vetter M, et al. Oncological patients in the intensive care unit: prognosis, decision-making, therapies and end-of-life care. Swiss Med Wkly. 2017;147(3132):w14481. doi: https://doi.org/10.4414/smw.2017.14481

Azevedo LCP, Caruso P, Silva UVA, et al. Outcomes for patients with cancer admitted to the ICU requiring ventilatory support: results from a prospective multicenter study. Chest. 2014;146(2):257-66. doi: https://doi.org/10.1378/chest.13-1870

HOL: Hospital Ophir Loyola [Internet]. Belém (PA): Hospital Ophir Loyola; c2018 [acesso 2021 Out 6]. Disponível em: http://www.ophirloyola.pa.gov.br

Conselho Nacional de Saúde (BR). Resolução nº 466, de 12 de dezembro de 2012. Aprova as diretrizes e normas regulamentadoras de pesquisas envolvendo seres humanos. Diário Oficial da União, Brasília, DF. 2013 jun 13; Seção 1:59.

Corrêa TD, Midega TD, Timenetsky KT, et al. Características clínicas e desfechos de pacientes com COVID-19 admitidos em unidade de terapia intensiva durante o primeiro ano de pandemia no Brasil: um estudo de coorte retrospectivo em centro único. Einstein (São Paulo). 2021;19:eAO6739. doi: https://doi.org/10.31744/einstein_journal/2021AO6739

Brar G, Pinheiro LC, Shusterman M, et al. COVID-19 severity and outcomes in patients with cancer: a matched cohort study. J Clin Oncol. 2020;38(33):3914-24. doi: https://doi.org/10.1200/JCO.20.01580

Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020;31(7):894-901. doi: https://doi.org/10.1016/j.annonc.2020.03.296

Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10(6):783-91. doi: https://doi.org/10.1158/2159-8290.CD-20-0422

Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97(5):829-38. doi: https://doi.org/10.1016/j.kint.2020.03.005

Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907-18. doi: https://doi.org/10.1016/S0140-6736(20)31187-9

Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-4. doi: https://doi.org/10.1016/S0140-6736(20)30628-0

Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020;395(10239):1763-70. doi: https://doi.org/10.1016/S0140-6736(20)31189-2

Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531-8. doi: https://doi.org/10.1007/s00392-020-01626-9

Alcântara RC, Silva Junior LCF, Arnozo GM, et al. Covid-19 em pacientes oncológicos: uma revisão do perfil clínico-epidemiológico. Rev Bras Cancerol. 2020;66(TemaAtual):e-1046. doi: https://doi.org/10.32635/2176-9745.RBC.2020v66nTemaAtual.1046

Stevanato KP, Dutra AC, Santos L, et al. Perfil epidemiológico das mortes por câncer de mama e covid-19. Res Soc Dev. 2021;10(8):e27210817269. doi: https://doi.org/10.33448/rsd-v10i8.17269

Maringe C, Spicer J, Morris M, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol. 2020;21(8):1023-51. doi: https://doi.org/10.1016/S1470-2045(20)30388-0

Downloads

Published

2023-01-31

How to Cite

1.
Oliveira AKB de, Araújo MS de, Alves SFL, Souza Filho LEC de, Silva ML da, Cunha K da C. Clinical Profile of Critical Oncological Patients with COVID-19. Rev. Bras. Cancerol. [Internet]. 2023 Jan. 31 [cited 2024 Dec. 26];69(1):e-133060. Available from: https://rbc.inca.gov.br/index.php/revista/article/view/3060

Issue

Vol. 69 No. 1 (2023): Jan./Feb./Mar.

Section

ORIGINAL ARTICLE

License

Os direitos morais e intelectuais dos artigos pertencem aos respectivos autores, que concedem à RBC o direito de publicação.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Most read articles by the same author(s)